william威廉亚洲官方

关于william威廉亚洲官方
研发服务
服务平台
客户中心
新闻资讯
投资者关系
人力资源
EN
×
EN

  • 营业咨询

    中国：

    Email: marketing@medicilon.com.cn

    营业咨询专线：400-780-8018

    （仅限服务咨询 ，其他事宜请拨打川沙总部电话）

    川沙总部电话: +86 (21) 5859-1500

    外洋：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在线留言×
点击切换
Customer Center
客户中心
Jul 06,2023
SKLB-YTH-60可改善博来霉素诱导的肺纤维化小鼠模子中的炎症和纤维化 ，YTH-60的体内药代动力学研究通过william威廉亚洲官方举行
Idiopathic pulmonary fibrosis is a chronic and lethal lung disease associated with fibroblast activation, myoblast proliferation and extracellular matrix deposition. SKLB-YTH-60 was developed through computer-aided drug design, de novo synthesis and high-throughput screening. YTH-60 has obvious anti‐proliferative activity on fibroblasts and A549 cells. YTH-60 has an acceptable oral bioavailability and appropriate eliminated half-life time. The in vivo pharmacokinetic study of YTH‐60 was performed by Medicilon.
审查更多
SKLB-YTH-60可改善博来霉素诱导的肺纤维化小鼠模子中的炎症和纤维化 ，YTH-60的体内药代动力学研究通过william威廉亚洲官方举行
Jul 06,2023
研究职员乐成发明了一种口服PROTAC降解剂SIAIS164018 ，具有优异的体内耐受性。PK和MTD研究通过william威廉亚洲官方举行
PROTAC is an attractive technology in drug discovery. Researchers successfully discovered an orally available PROTAC degrader SIAIS164018 which degrades not only ALK or mutant EGFR but also oncoproteins involved in metastasis. SIAIS164018 is orally bioavailable and well tolerated in vivo. Pharmacokinetic and maximal tolerated dose (MTD) assays were performed by Medicilon.
审查更多
研究职员乐成发明了一种口服PROTAC降解剂SIAIS164018 ，具有优异的体内耐受性。PK和MTD研究通过william威廉亚洲官方举行
Jul 06,2023
开发具有口服活性的高度选择性卵泡刺激激素受体激动剂 ，且举行临床前研究。其中对大鼠和狗的毒理学评估通过william威廉亚洲官方举行
TOP5300 is an orally active follicle stimulating hormone receptor allosteric agonist that provides a preferred treatment for over 16 million infertile women of reproductive age in low complexity methods or in high complexity methods. TOP5300 was evaluated in standard ADME, including Cytochrome P450 inhibition, clearance and pharmacokinetic profiles. Toxicological evaluations were performed in both rat and dog as the second species according to the guidance from FDA. These assays were performed by Medicilon.
审查更多
开发具有口服活性的高度选择性卵泡刺激激素受体激动剂 ，且举行临床前研究。其中对大鼠和狗的毒理学评估通过william威廉亚洲官方举行
Jul 06,2023
PARP1/2抑制剂有治疗肿瘤的潜力 ，PARP1/2抑制实验通过william威廉亚洲官方举行
Poly ADP-ribose polymerases (PARPs) are a family of enzymes related to DNA damage repair process. Inhibition of PARP1/2 accelerates the damage of injured DNA, which is synthetically lethal to DNA-repairing-deficient cancer cells, such as BRCA1/2-deficient cells. PARP1/2 inhibitors could be a promising candidate for the treatment of cancer. The PARP1 and PARP2 inhibition assays were performed by Medicilon.
审查更多
PARP1/2抑制剂有治疗肿瘤的潜力 ，PARP1/2抑制实验通过william威廉亚洲官方举行
Jul 06,2023
使用william威廉亚洲官方硒代氨基酸作育基产品揭晓的学术文献
william威廉亚洲官方提供全套M9硒代蛋氨酸（SeMET）作育基 ，可用于IPTG诱导的大肠杆菌表达系统 ，生产硒代蛋氨酸标记的卵白 ，运用多波长变态散射（MAD）要领举行卵白质晶体学研究。
审查更多
使用william威廉亚洲官方硒代氨基酸作育基产品揭晓的学术文献
Jul 05,2023
设计合成一种高度选择性的H435R突变敏感的甲状腺激素受体β激动剂 ，PK剖析通过william威廉亚洲官方举行
Thyroid hormone receptors (TRs) are ligand-dependent transcription factors that belong to the nuclear receptor superfamily and also participate in important physiological functions. In this study, Compound 16g is a well-characterized selective and mutation-sensitive TRβ agonist for further investigating its function in treating dyslipidemia, nonalcoholic steatohepatitis (NASH), and resistance to thyroid hormone (RTH). Compound 16g showed excellent lipid metabolism, safety, metabolic stability, and pharmacokinetic properties. PK properties of Compound 16g were analyzed by Medicilon.
审查更多
设计合成一种高度选择性的H435R突变敏感的甲状腺激素受体β激动剂 ，PK剖析通过william威廉亚洲官方举行
Jul 05,2023
研究职员设计合成STAT3和HDAC双通路抑制剂用于治疗实体肿瘤 ，PK实验通过william威廉亚洲官方举行
The inhibition of HDACs will lead to compensated activation of a notorious cancer-related drug target, STAT3, in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDAC inhibitors in solid tumors. Herein, researchers synthesized a series of potent pterostilbene hydroxamic acid derivatives with dual-target inhibition activity. The pharmacokinetic experiment in SD Rats was carried out by Medicilon.
审查更多
研究职员设计合成STAT3和HDAC双通路抑制剂用于治疗实体肿瘤 ，PK实验通过william威廉亚洲官方举行
Jul 05,2023
阿帕替尼通过VEGFR2通路抑制紫杉醇对胃癌细胞的耐药性
Overexpression of VEGFR2 can offset the rescue effect of Apatinib on Paclitaxel-induced drug resistance of MGC803 cells. Apatinib inhibits Paclitaxel resistance of MGC803 cells via the VEGFR2 signaling pathway. In this research, the VEGFR2 sequences were designed and then amplified by RT-PCR. The sequences were then ligated with a pcDNA3.0 plasmid to construct a recombinant pcDNA3.0-VEGFR2 vector (Medicilon).
审查更多
阿帕替尼通过VEGFR2通路抑制紫杉醇对胃癌细胞的耐药性
Jul 05,2023
研究职员报告了一种具有细胞渗透性的选择性METTL3纳摩尔抑制剂UZH1a ，作者谢谢william威廉亚洲官方合成了UZH1a和UZH1b
The methylase METTL3 is the writer enzyme of the N6‐methyladenosine (m6A) modification of RNA. Here researchers report a nanomolar inhibitor of METTL3 (UZH1a) which is selective and cell‐permeable, while its enantiomer UZH1b is essentially inactive. The authors thank Medicilon for the synthesis of the UZH1a and UZH1b compounds.
审查更多
研究职员报告了一种具有细胞渗透性的选择性METTL3纳摩尔抑制剂UZH1a ，作者谢谢william威廉亚洲官方合成了UZH1a和UZH1b
Jul 05,2023
研究职员设计并合成了一种光笼PI3K抑制剂1 ，它可以通过紫外线照射激活 ，释放出高效PI3K抑制剂2�；衔�1和2的ADME研究通过william威廉亚洲官方举行
Aberrant activation of the PI3K pathway has been intensively targeted for cancer therapeutics for decades. In this work, researchers designed and synthesized a novel photocaged PI3K inhibitor 1, which could be readily activated by UV irradiation to release a highly potent PI3K inhibitor 2. ADME studies of compounds 1 and 2 were conducted by Medicilon. Medicilon's pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody.
审查更多
研究职员设计并合成了一种光笼PI3K抑制剂1 ，它可以通过紫外线照射激活 ，释放出高效PI3K抑制剂2�；衔�1和2的ADME研究通过william威廉亚洲官方举行
×
搜索验证
点击切换
网站地图
友情链接：黄金城网站  沙巴sb体育  yd2333云顶电子游戏  庄闲官网  金狮贵宾会3420055  cq9电子  皇冠hg1088  纳米体育  美狮贵宾会  jdb电子游戏平台  AG旗舰厅  尊龙官方入口  必一运动  amjs澳金沙门  ok138太阳集团